A Chikungunya Vaccine Just Vanished from the U.S.

The Numbers Behind the Business Problem

Even before the safety crisis, IXCHIQ was struggling commercially. Valneva had projected the vaccine would exceed €100 million in annual sales by its third year on the market. The reality? In the first nine months of 2024, U.S. sales totaled just €1.8 million. First-half 2025 sales reached €7.5 million, a big percentage jump from a tiny base.

Valneva's overall business isn't collapsing; the company reported €157.9 million in total product sales for 2025, driven largely by its other vaccines. It also secured a $500 million debt facility from Pharmakon, with an initial $215 million tranche to refinance existing obligations. The stock, trading around $5.38 on NASDAQ in mid-June 2026, still carries analyst price targets near $12, suggesting some believe in the broader portfolio.

But IXCHIQ was supposed to be the growth engine. Without it, Valneva's 2026 revenue guidance of €145–160 million looks like a company treading water rather than accelerating.

A Disease That Isn't Going Away

The timing of this withdrawal is especially painful because chikungunya is surging globally. WHO received reports of over 500,000 cases across 41 countries in 2025, with 186 deaths. The Americas are the current hotspot: Brazil, Bolivia, Cuba, and Argentina are all reporting significant outbreaks, and transmission has re-emerged in areas that had been quiet for years, including Guyana, French Guiana, and Suriname.

Chikungunya won't kill most people who catch it, but it can be genuinely miserable. The hallmark symptom is severe joint pain so intense that the disease's name, in the Makonde language, roughly translates to "that which bends up." Some patients develop chronic arthritis lasting months or longer. Infants, elderly adults, pregnant women, and people with underlying conditions face the highest risk of serious complications.

With no vaccine available in the U.S., prevention comes down to one strategy: don't get bitten. That means repellent, long sleeves, and screened rooms. For the millions of travelers heading to endemic regions each year, that's the entire toolkit now.

The Bigger, Uglier Question

IXCHIQ's collapse illuminates a problem that haunts global health: niche tropical disease vaccines are almost impossible to make commercially viable. The people most affected tend to live in low-income countries with weak procurement systems. The paying market (mostly Western travelers) is small and unpredictable. R&D costs are enormous, and the regulatory bar is high.

Consider the track record. Candidates for hookworm, schistosomiasis, and leishmaniasis remain stuck in early-stage trials because no company sees a return worth chasing.

Valneva actually got further than almost anyone. It brought a tropical disease vaccine from concept to FDA approval, a feat that most neglected-disease programs never achieve. The fact that even this success story ended in withdrawal tells you something uncomfortable about the economics of protecting vulnerable populations.

What Comes Next

Valneva says it will "continue reviewing IXCHIQ's global product opportunity" and may pursue post-marketing studies outside the U.S. in coordination with other regulators. The EMA had temporarily suspended use in older adults in May 2025 but lifted the restriction by September 2025 after completing its safety review; IXCHIQ remains authorized in Europe for all ages under strict risk-benefit conditions, though a separate European decision on the vaccine's future could still go either way.

For the U.S., though, the chapter is closed. A chikungunya vaccine arrived, stumbled on safety, couldn't find a commercial foothold, and exited in under three years. Meanwhile, Aedes mosquitoes are expanding their territory, fueled by climate change and urbanization, carrying chikungunya into new regions with little population immunity.

It's a familiar paradox in global health: the diseases that need vaccines the most are the ones the market is least equipped to deliver. IXCHIQ was supposed to break that pattern. Instead, it became another example of it.

The Cancer Company That Just Bought a Lung Drug

Zymeworks, an oncology biotech known for its HER2-targeting cancer drugs, just dropped $929 million to buy a COPD lung treatment. The financing structure is clever, the strategic logic is surprisingly sound, and the real test comes in August.